Expression of epidermal growth factor receptor in gestational trophoblastic diseases

Abstract

Gestational trophoblastic disease is an abnormal condition of the placenta, the incidence of which is very high in the State of Kerala, India. The biology of this disease is vague and methods to determine the malignant potential are limited. Placentae of normal (50) and molar pregnancies (95), including 32 showing persistent disease, were used for the study. Epidermal growth factor (EGFR), expression was evaluated by immunohistochemistry using monoclonal antibody, and quantified using the 125I-EGF-binding assay. EGFR was expressed more strongly in molar placentae than in normal placentae of similar gestational age, and was strong in the molar placentae of all gestational ages, whereas expression was mainly restricted to the first and second trimesters in normal placentae. Moles with early presenting symptoms (before 16 weeks) were at a higher risk of developing persistent disease. To conclude, the immunohistochemical study shows high expression of EGFR in early normal placentae and in moles, linking its role to the proliferative and differentiating activity of trophoblasts. Tumours with a histological diagnosis of invasive moles and choriocarcinoma showed very strong binding of EGFR. The present observations also suggest the possibility of mutated EGF receptors being present in persistent trophoblastic disease.

Epidermal growth factor receptor is a marker for syncytiotrophoblastic cells in testicular germ cell tumors

“…EGFR expression was also found in syncytiotrophoblastic cells, either as components of choriocarcinoma or scattered as single cells in other types of TGCT. This expression pattern corresponds to previous observations that EGFR is expressed in the implantation trophoblast, in the trophoblast of normal placenta and in gestational trophoblastic diseases [1,7,10,11,22].…”